Mountain Valley MD Provides Business Update
The Company has been working towards commercialization of its three core lines of business, which are: a) novel innovations that are designed to improve the administration and efficacy of nutraceutical health and wellness products, b) an agricultural plant signaling technology that is designed to organically drive increases in crop yields and supports the reduction of fertilizer usage where used, and c) the application of solubilized drugs to positively impact the health of husbandry animals and aquatic species.
“The MVMD team and our extensive network of partners has been making significant progress on our commercialization objectives,” stated Dennis Hancock, President & CEO of Mountain Valley MD. “It is great to see such tangible progress in support of our business objectives and our vision to positively impact human, plant and animal health.”
LINE OF BUSINESS UPDATES:
NUTRACEUTICALS
General and MVMD Proprietary Brands
Following evaluation of North American GMP manufacturing options for MVMD’s nutraceutical product strategy, the Company entered into a license agreement with its selected third-party lead production partner in
Securing the Lead Manufacturer and finalizing the scaled GMP production environment aligns with MVMD’s anticipated increased business development efforts that will support the Company’s plans to secure additional nutraceutical licensing partnerships.
Mountains Of… Proprietary Brand
The Lead Manufacturer has been working closely with the Company’s formulators on dissolution, flavouring, and production elements for MVMD’s proprietary product line, “Mountains Of … “. Additionally, the Lead Manufacturer has invested in the expansion of its manufacturing facility since March 2023 to provide dedicated space for the specialized equipment that MVMD requires to manufacture nutraceutical products that embody the Company’s Quicksome™ technologies. It is anticipated that full production readiness for MVMD”s proprietary brand products will be achieved in the fall of calendar 2023.
In the fall of 2022 calendar year, the Company applied for, and successfully received, trademark protection for “MOUNTAINS OF” SLEEP, ENERGY, RELIEF, LIBIDO, and LEAN, for its initial GMP product sample development. The “MOUNTAINS OF …” brand will be used for business development activities focused on securing additional nutraceutical distribution partners that can choose to use the “MOUNTAINS OF” product line or produce proprietary versions with their company’s own branding and packaging requirements.
Circadian Wellness Corp.
MVMD and the Lead Manufacturer have continued work to support the license agreement between the Company and Circadian Wellness Corp. (“Circadian”), an MVMD licensee, to finalize the proprietary formulations for mushroom-infused products that Circadian intends to market under its Eons brand and to finalize the GMP production environment. Circadian’s license from MVMD supports the desire to achieve an increase in overall molecule efficacy with the Company’s Quicksome™ technology applied across a variety of rapid dissolve sublingual and dermal products in the functional mushroom space. The initial product formulation work and dissolution testing has been positive in MVMD’s view and the recent advancements made in the 2023 calendar year align with the anticipated timing to proceed with commercial manufacturing in the fall of calendar 2023. As per the licensing framework with Circadian, the Company is entitled to fees and/or royalties from Circadian for its proprietary formulation work with the application of the Quicksome™ technology to proprietary mushroom-infused formulations.
It is anticipated that Circadian will be introducing a variety of consumer mushroom-infused sublingual products that embody MVMD’s technology under its Eons brand for sale in
AGRICULTURE
By virtue of a license arrangement with Agrarius Corp. (“AC”), a private US corporation and owner of Agrarius technology and related products, MVMD is an authorized reseller of Agrarius, a certified organic product owned by AC. The Agrarius product is delivered in a liquid concentrate form that gets mixed with water at the point of application and then applied via sprayer to agricultural crops ideally twice during a plant’s lifecycle. The Agrarius product has been tested across numerous major agricultural crops, and has demonstrated its ability to naturally increase crop yields from approximately ten to fifty percent or more depending on crop type, reduce fertilizer usage where used by more than thirty percent, and increase general resilience to pests and climate change forces such as drought.
The Agrarius product works by activating the plants’ “defense mechanisms” at the cellular level, without the actual stress factor. The intended effect of the Agrarius product is that treated plants grow deeper roots and open up their foliage to optimize the effect of photosynthesis, thus increasing growth hormones, plant efficiency for water use and nutrients, decreasing the requirement of fertilizer where used, and increasing overall resistance to diseases and stressed climate conditions. Agrarius technology enables direct plant communication by mimicking naturally occurring organic molecules that correspond to various plant survival instincts, which improves the natural defence mechanisms of the plant to overcome environmental stresses. The Agrarius product works by sending signals that a plant understands and propagates through its roots and mycelial networks, allowing nearby plants to benefit from the signals naturally while reducing the actual amount of product that is used on a field. These signals literally send information that stimulates plant growth, subsequently increasing yields, volatility resistance, and growth speeds.
Agrarius received organic certification through the Organic Materials Review Institute (OMRI). According to its website (omri.org), OMRI is a non-profit organization that provides an independent review of products, such as fertilizers, pest controls, livestock health care products, and numerous other inputs that are intended for use in certified organic production and processing. OMRI reviews products against organic standards and once approved, acceptable products appear on the OMRI Products Lists© on their company website.
MVMD believes Agrarius presents a significant opportunity to support its growth objectives given the rapidly changing global agricultural landscape due to mass fertilizer shortages, population growth, and urban sprawl limiting available farmlands and has focused its recent resources on the development of this line of business. MVMD is currently conducting business development activity in
MVMD has hired key team members in
The Company plans to operate its LATAM sales operations primarily through a wholly owned subsidiary in
HUSBANDRY ANIMALS / AQUATIC SPECIES
The Company has applied its Quicksol™ solubilization technology to the drug Ivermectin to create its Soluvec™
The Company’s overall husbandry and aquatic species strategy was to develop its scientific assets with a view to licensing to third parties. As previously disclosed on May 8, 2023, the Company entered into a license agreement with a privately held
Related to the license agreement and necessary government approvals, the pharmacokinetic trials conducted inside
The Company has made a significant time and financial investment over the past approximately 18 months in an effort to optimize a final formulation approach to ensure its Soluvec™
Management believes that commercialization of Soluvec™
The Company continues to evaluate the opportunity to license its Soluvec™
The Company announced on August 9, 2023 the peer-reviewed publication of its Soluvec™ study data in the journal, Therapeutic Delivery. The published study highlights the benefits of the Company’s patented Soluvec™ formulation, a novel, solvent-free aqueous Ivermectin invention. The study confirmed that parenteral administration of Soluvec™ led to an Ivermectin drug exposure approximately seven times higher than traditional oral drug dosing, with greater bioavailability, offering potential for enhanced therapeutic effectiveness.
ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.
Mountain Valley MD is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations:
- patented Quicksome™ oral formulation and delivery technologies,
- patented Quicksol™ solubility formulation technology
- licensed product reseller of Agrarius™, a novel agricultural plant signalling technology
Consistent with its vision towards “More Life”, MVMD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, MVMD’s work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.
MVMD’s patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy.
MVMD’s patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.
MVMD’s licensed Agrairus™ agricultural plant signalling technology that could be capable of application to agricultural crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.
For more Company information and contact details, visit www.MVMD.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.
The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company.
The Company is making forward-looking statements, including but not limited to: the Company’s three (3) lines of business to achieve commercialization; the strategy of engaging one Lead Manufacturer and the impact thereof; the anticipated increase in business development efforts to secure additional nutraceutical licensing partnerships; timing for the full production readiness for MVMD”s proprietary brand products; the timing of commercial manufacturing for Circadian, including the mushroom-infused products under the Eons brand; the potential multi-million dollar field coverage pipeline from trialing Agrarius customers; the timing of anticipated revenues and related ramp-up of sales growth; plans and structure related to LATAM operations, and the impacts thereof, including tax benefits; the registration process, the territories, and the timing thereof; the timing of commercialization of Soluvec™
The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
Neither the CSE nor OTC has reviewed or approved the contents of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230810893962/en/
For further information:
Dennis Hancock
President and Chief Executive Officer
Mountain Valley MD Holdings Inc.
Investor Relations @ 647-725-9755
Email: info@mvmd.com
www.MVMD.com
Source: Mountain Valley MD Holdings Inc.